SABSW | SAB Biotherapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0800 - 0.0940
52 Week Range	0.0800 - 0.0940
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	11,662
Average Volume	N/A
Shares Outstanding	9,229,270
Market Cap	830,634
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-10-25

Valuation
Profitability
Growth
Health
P/E Ratio	0.31
Forward P/E Ratio	N/A
EPS	0.29
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	57
Country	USA
Website	SABSW

SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.

SABSW's peers: CING, EDSA, NRXP, SABS, JSPRW, NRXPW, ROIVW, SRZNW, SNTI, REVBW, IMNN, MLECW

*Chart delayed

Analyzing fundamentals for SABSW we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see SABSW Fundamentals page.

Watching at SABSW technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on SABSW Technicals page.